Table 1.
Baseline characteristics of the ovarian cancer cases and controls
| Characteristic | Cases | Controls |
|---|---|---|
| All women | 237 | 427 |
| Parent cohort | ||
| NSHDS, Sweden (borderline) | 132 (23) | 235 (40) |
| NYUWHS, USA | 58 | 99 |
| ORDET, Italy (borderline) | 47 (7) | 93 (14) |
| Lag-time to cancer diagnosis, mean (SD) | 6.5 (4.0) | – |
| Diagnosed within two years (%) | 35 (15%) | – |
| Diagnosed between two and five years (%) | 58 (25%) | – |
| Histology (%) | ||
| Serous | 133 (56%) | – |
| Mucinous | 29 (12%) | – |
| Endometrioid | 29 (12%) | – |
| Clear cell | 15 (6%) | – |
| Undifferentiated | 7 (3%) | – |
| Other | 4 (2%) | – |
| NOS | 19 (8%) | – |
| Missing | 1 (1%) | – |
| Menopausal status (%) | ||
| Premenopausal | 88 (37%) | 157 (37%) |
| Postmenopausal | 143 (60%) | 260 (61%) |
| Peri-menopausal/unmatched | 6 (3%) | 10 (2%) |
| Parity (%) | ||
| Nulliparous | 44 (19%) | 54 (13%) |
| Parous | 156 (66%) | 335 (78%) |
| Unknown | 37 (16%) | 38 (9%) |
| Previous OC use (%) | ||
| Never | 134 (57%) | 233 (55%) |
| Ever | 64 (27%) | 137 (32%) |
| Unknown | 39 (16%) | 57 (13%) |
| Previous HRT use (%)a | ||
| Never | 67 (47%) | 171 (66%) |
| Ever | 45 (31%) | 60 (23%) |
| Unknown | 31 (22%) | 29 (11%) |
| Smoking status (%) | ||
| Non Smokers | 102 (43%) | 212 (50%) |
| Ex-smokers | 24 (10%) | 41 (10%) |
| Current smokers | 62 (26%) | 91 (21%) |
| Unknown | 49 (21%) | 83 (19%) |
| BMI (mean, SD) | 25.5 (4.0) | 25.8 (4.2) |
| BMI (%) | ||
| <25 | 113 (48%) | 186 (44%) |
| 26–29 | 82 (35%) | 147 (34%) |
| 30+ | 27 (11%) | 66 (15%) |
| Unknown | 15 (6%) | 28 (7%) |
| Diabetes (%) | ||
| No | 170 (72%) | 337 (79%) |
| Yes | 11 (5%) | 17 (4%) |
| Unknown | 56 (24%) | 73 (17%) |
a
Among postmenopausal women